The World Health Organisation (WHO) has given approval for two new treatments against Covid-19: baricitinib and sotrovimab.
Baricitinib, used until now for the treatment of rheumatism, is strongly recommended in combination with corticosteroids for people severely affected by Covid-19, according to a WHO opinion published in the medical journal The BMJ.
The WHO’s recommendation for the monoclonal antibody sotrovimab is conditional, suggested for use in patients with non-severe Covid-19, “but only in those at highest risk of hospital admission, reflecting fewer benefits in those at lower risk.”
“The latest recommendations are based on evidence from seven trials involving over 4000 patients with non-severe, severe, and critical Covid-19,” the opinion reads.
The WHO experts note that baricitinib works in a similar way to interleukin-6 inhibitors, which have already received the organisation’s approval.
When both drugs are available, the WHO suggests choosing one on the basis of cost, availability, and clinician experience.
It does not recommend using both drugs at the same time.